140 completed, 38 unknown, 32 recruiting, 11 not yet recruiting. 75 Phase 2, 46 Phase 3, 42 Phase 1, 38 Phase 4, 14 Not applicable.
Follow this drug Literature Review of tofacitinib trials Research Report on tofacitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study Topical 2% Tofacitinib - Nail Psoriasis | Phase 2 | Active not recruiting | Hexsel Dermatology Clinic | 10 | 2026-09-01 | 2026-09-25 |
| A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL Venetoclax + Tofacitinib, Venetoclax+ Everoliumus +Enrylaze, Venetoclax + 5 Azacitidine - LAL | Phase 2 | Not yet recruiting | Philippe ROUSSELOT | 93 | 2026-09-01 | 2026-04-17 |
| A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers Upadacitinib, Tofacitinib, Baricitinib - Healthy Volunteers | Phase 1 | Recruiting | AbbVie | 60 | 2026-08-26 | 2026-09-28 |
| Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis Tofacitinib, Imatinib, tofacitinib Placebo - Palmoplantar Pustulosis (PPP) | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 135 | 2026-08-01 | 2026-08-03 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis TQH3906 Capsule, TQH3906 Placebo Capsule, Tofacitinib Citrate Tablet 5 mg - Psoriatic Arthritis | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 156 | 2026-07-16 | 2026-09-02 |
| Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis Methotrexate, Tofacitinib - Chronic Plaque Psoriasis | Not applicable | Not yet recruiting | Pak Emirates Military Hospital | 88 | 2026-06-01 | 2026-05-12 |
| Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1 Tofacitinib Oral Solution, Placebo - Down Syndrome | Phase 2 | Recruiting | University of Colorado, Denver | 92 | 2026-05-28 | 2026-09-03 |
| Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease Tofacitinib - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 8 | 2026-04-24 | 2026-04-29 |
| Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis | Active not recruiting | Pfizer | 4000 | 2026-04-01 | 2026-10-15 | |
| Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) Tofacitinib, Methotrexate - Alopecia Areata, Alopecia Totalis (AT) | Phase 4 | Not yet recruiting | Hayat Abad Medical Complex, Peshawar | 78 | 2026-02-15 | 2026-02-12 |
| The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea Doxycycline, Hydroxychloroquine, Tofacitinib - Erythematotelangiectatic Rosacea | Not applicable | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 186 | 2026-02-01 | 2026-03-24 |
| Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab - Polyarticular Course Juvenile Idiopathic Arthritis (JIA) | Phase 3 | Recruiting | Duke University | 400 | 2026-01-09 | 2026-10-21 |
| A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD) guselkumab (GUS), JAK inhibitors (such as upadacitinib/tofacitinib) - Inflamatory Bowel Disease | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 80 | 2026-01-07 | 2026-03-23 | |
| Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial Infliximab, Tofacitinib - Acute Severe Ulcerative Colitis | Phase 2 | Not yet recruiting | Asian Institute of Gastroenterology, India | 60 | 2026-01-01 | 2025-12-24 |
| Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease Tofacitinib - Sjogren's Syndrome | Phase 2 | Recruiting | National Institute of Dental and Craniofacial Research (NIDCR) | 60 | 2025-12-18 | 2026-10-19 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL Tofacitinib 5 MG - Rheumatoid Arthritis, Major Adverse Cardiac Events | Phase 4 | Recruiting | Shaikh Zayed Hospital, Lahore | 120 | 2025-12-06 | 2026-04-28 |
| Tofacitinib in Juvenile Idiopathic Arthritis Tofacitinib - Juvenile Idiopathic Arthritis (JIA) | Not yet recruiting | Consorci Sanitari de l'Alt Penedès i Garraf | 58 | 2025-12-01 | 2025-11-26 | |
| Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus Tofacitinib 5 mg BID and Triamcinolone ointment, Placebo and Triamcinolone ointment - Oral Lichen Planus | Phase 4 | Recruiting | All India Institute of Medical Sciences, Bhubaneswar | 60 | 2025-10-10 | 2025-11-28 |
Showing 20 of 243. Sign in to see all of them.
Arthritis, Rheumatoid (72) · Colitis, Ulcerative (18) · Psoriasis (16) · Arthritis, Psoriatic (13) · Alopecia Areata (9) · Arthritis, Juvenile (8) · Bronchiolitis Obliterans Syndrome (7) · Lymphoma, Follicular (7) · Pruritus (7) · Dermatitis, Atopic (6) · Alopecia universalis (5) · Arthritis (5) · Autoimmune Diseases (5) · COVID-19 (5) · Crohn Disease (5)
Pfizer (92) · Second Affiliated Hospital, Zhejiang University, School of Medicine (9) · Shanghai Zhongshan Hospital (6) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (5) · Brigham and Women's Hospital (3) · CAGE Bio Inc. (3) · Peking University People's Hospital (3) · University of Colorado, Denver (3) · Vastra Gotaland Region (3) · Charite University, Berlin, Germany (2) · Chinese SLE Treatment And Research Group (2) · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (2) · GlaxoSmithKline (2) · Globe Pharmaceuticals Limited (2) · Hangzhou Highlightll Pharmaceutical Co., Ltd (2)
United States (106) · China (51) · Germany (42) · Canada (41) · Poland (41) · Spain (41) · Czechia (35) · South Korea (34) · Hungary (31) · Australia (30) · Belgium (28) · France (27) · Mexico (27) · Russia (27) · Slovakia (27)
Lindi Jiang, PhD (4) · Joaquin Espinosa, PhD (3) · Zhanguo Li (3) · Blake M Warner, D.D.S. (2) · Chinmanat Lekhavat, MD (2) · Yoon-Kyoung Sung, MD, PhD, MPH (2) · Aflak Rasheed, FCPS (1) · Anna-Karin H Ekwall, MD MSc PhD (1) · Anthony E Oro, M.D., Ph.D. (1) · Asadul Islam, MBBS (1) · Benjamin Terrier, MD, PhD (1)
PMID 32816215, PMID 36931693, PMID 36526796, PMID 34870800, PMID 36600185, PMID 36601090, PMID 33127856, PMID 28143815, PMID 39192350, PMID 25047021, PMID 38958913, PMID 37453736, PMID 26275429, PMID 36814062, PMID 34921355, PMID 28941219, PMID 30177460, PMID 35577477, PMID 37925660, PMID 29949132, PMID 33057725, PMID 33059710, PMID 35648151, PMID 36124702, PMID 38425446, PMID 38883150, PMID 41448717, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32766762, PMID 32870265, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35792493, PMID 36336750, PMID 36342120, PMID 37402275, PMID 37560161, PMID 38298058, PMID 38696034, PMID 38778549, PMID 40241921, PMID 28467869, PMID 29028981, PMID 29435359, PMID 29743836, PMID 31112005
2023 (3), 2014 (2), 2016 (2), 2017 (2), 2018 (2), 2019 (2), 2008 (1), 2009 (1), 2015 (1), R01HL148185 (1), R33AR077495 (1)